Skip to main content
Erschienen in: Endocrine 1/2013

01.08.2013 | Original Article

Expression and significance of IGF-1 and IGF-1R in thyroid nodules

verfasst von: Ying-Jian Liu, Wei Qiang, Jing Shi, Si-Qing Lv, Mei-Ju Ji, Bing-Yin Shi

Erschienen in: Endocrine | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

There are limitations in the diagnosis of thyroid nodules, especially follicular lesions, and their pathogenesis remains unclear. Insulin-like growth factor-1 (IGF-1) has been implicated in tumor cell apoptosis, transformation, invasion, and metastasis; however, its role in thyroid nodules is undetermined. The aim of this study is to investigate the relationship between expression of IGF-1 and thyroid nodule, and evaluate the role of IGF-1 in differential diagnosis and pathogenetic function of benign and malignant thyroid nodules. Sixty-two paraffin-embedded thyroid tissues from patients with thyroid nodules were selected, including 18 follicular adenomas (FA), 17 nodular goiters, 13 papillary thyroid carcinomas (PTC), 2 follicular thyroid carcinomas, and 12 normal controls. IGF-1 and IGF-1R protein and mRNA expression was detected by immunohistochemistry (IHC) and real-time quantitative PCR (qRT-PCR), respectively. Grouping comparisons were employed among the above groups based on the clinical and pathological subtypes. IGF-1 and IGF-1R expression was significantly higher in FA, nodular goiters, and PTC than that in the controls (all P < 0.01). Similarly, IGF-1 mRNA expression was also significantly higher in FA (P < 0.05), nodular goiters (P < 0.01), and PTC (P < 0.01) compared with the controls. IGF-1R mRNA expression was also significantly higher in FA, nodular goiters, and PTC (all P < 0.01) compared with the controls. Compared with FA and nodular goiters, PTC showed significantly higher IGF-1 and IGF-1R protein (P < 0.01, P < 0.05, respectively) and mRNA expression (P < 0.01, P < 0.05, respectively). IGF-1 probably plays an important role in the genesis and development of certain solid cold thyroid nodules, including PTC, nodular goiters, and FA. Detection of IGF-1 and IGF-1R expression in thyroid tissues by IHC or qRT-PCR is hard to distinguish malignant from benign lesions.
Literatur
1.
Zurück zum Zitat J.I. Jones, D.R. Clemmons, Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16(1), 3–34 (1995)PubMed J.I. Jones, D.R. Clemmons, Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16(1), 3–34 (1995)PubMed
2.
Zurück zum Zitat D. LeRoith, C.T. Roberts, The insulin-like growth factor system and cancer. Cancer Lett. 195(2), 127–137 (2003)PubMedCrossRef D. LeRoith, C.T. Roberts, The insulin-like growth factor system and cancer. Cancer Lett. 195(2), 127–137 (2003)PubMedCrossRef
3.
Zurück zum Zitat P. Tita, M.R. Ambrosio, C. Scollo et al., High prevalence of differentiated thyroid carcinoma in acromegaly. Clin. Endocrinol. (Oxf). 63(2), 161–167 (2005)PubMedCrossRef P. Tita, M.R. Ambrosio, C. Scollo et al., High prevalence of differentiated thyroid carcinoma in acromegaly. Clin. Endocrinol. (Oxf). 63(2), 161–167 (2005)PubMedCrossRef
4.
Zurück zum Zitat H.C. Alpay, T. Kalıdag, E. Keles et al., The effects of fine needle biopsy on thyroid hormone levels. Otolaryngol. Head Neck Surg. 136(6), 942–945 (2007)PubMedCrossRef H.C. Alpay, T. Kalıdag, E. Keles et al., The effects of fine needle biopsy on thyroid hormone levels. Otolaryngol. Head Neck Surg. 136(6), 942–945 (2007)PubMedCrossRef
5.
Zurück zum Zitat M. Gasperi, E. Martino, L. Manetti et al., Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J. Endocrinol. Invest. 25(3), 240–245 (2002)PubMed M. Gasperi, E. Martino, L. Manetti et al., Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J. Endocrinol. Invest. 25(3), 240–245 (2002)PubMed
6.
Zurück zum Zitat M. Scacchi, M. Andrioli, C. Carzaniqa et al., Elastosonogra evaluation of thyroid nodules in acromegaly. Eur. J. Endocrinol. 161(4), 607–613 (2009)PubMedCrossRef M. Scacchi, M. Andrioli, C. Carzaniqa et al., Elastosonogra evaluation of thyroid nodules in acromegaly. Eur. J. Endocrinol. 161(4), 607–613 (2009)PubMedCrossRef
7.
Zurück zum Zitat G. Siegel, Y. Tomel, Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature. Endocr. Res. 31(1), 51–58 (2005)PubMedCrossRef G. Siegel, Y. Tomel, Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature. Endocr. Res. 31(1), 51–58 (2005)PubMedCrossRef
8.
Zurück zum Zitat Y.J. Liu, W. Qiang, X.J. Liu et al., Association of insulin-like growth factor-1 with thyroid nodules. Oncol. Lett. 2(6), 1297–1301 (2011)PubMed Y.J. Liu, W. Qiang, X.J. Liu et al., Association of insulin-like growth factor-1 with thyroid nodules. Oncol. Lett. 2(6), 1297–1301 (2011)PubMed
9.
Zurück zum Zitat H. Hartog, J. Wesseling, H.M. Boezen et al., The insulin-like growth factor 1 receptor in cancer old focus, new future. Eur. J. Cancer 43(13), 1895–1904 (2007)PubMedCrossRef H. Hartog, J. Wesseling, H.M. Boezen et al., The insulin-like growth factor 1 receptor in cancer old focus, new future. Eur. J. Cancer 43(13), 1895–1904 (2007)PubMedCrossRef
10.
Zurück zum Zitat R. Baserga, The insulin-like growth factor-1 receptor as a target for cancer therapy. Expert. Opin. Ther. Targets 9(4), 753–768 (2005)PubMedCrossRef R. Baserga, The insulin-like growth factor-1 receptor as a target for cancer therapy. Expert. Opin. Ther. Targets 9(4), 753–768 (2005)PubMedCrossRef
11.
Zurück zum Zitat D. Sachdev, D. Yee, Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 6(1), 1–12 (2007)PubMedCrossRef D. Sachdev, D. Yee, Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 6(1), 1–12 (2007)PubMedCrossRef
12.
13.
Zurück zum Zitat R. Baserga, The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 55(2), 249–252 (1995)PubMed R. Baserga, The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 55(2), 249–252 (1995)PubMed
14.
15.
Zurück zum Zitat P. Rotwein, Structure, evolution, expression and regulation of insulin-like growth factors I and II. Growth Factors 5(1), 3–18 (1991)PubMedCrossRef P. Rotwein, Structure, evolution, expression and regulation of insulin-like growth factors I and II. Growth Factors 5(1), 3–18 (1991)PubMedCrossRef
16.
Zurück zum Zitat W. Chao, P.A. D’Amore, IGF-2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 19(2), 111–120 (2008)PubMedCrossRef W. Chao, P.A. D’Amore, IGF-2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 19(2), 111–120 (2008)PubMedCrossRef
17.
Zurück zum Zitat E.J. Mason, J.A. Grell, J. Wan et al., Insulin-like growth factor (IGF)-I and IGF-II contribute differentially to the phenotype of pregnancy associated plasma protein-A knock-out mice. Growth Horm IGF Res. 21(5), 243–247 (2011)PubMedCrossRef E.J. Mason, J.A. Grell, J. Wan et al., Insulin-like growth factor (IGF)-I and IGF-II contribute differentially to the phenotype of pregnancy associated plasma protein-A knock-out mice. Growth Horm IGF Res. 21(5), 243–247 (2011)PubMedCrossRef
18.
Zurück zum Zitat E. Maiorano, A. Ciampolillo, G. Viale et al., Insulin-like growth factor 1 expression in thyroid tumors. Appl. Immunohistochem. Mol. Morphol. 8(2), 110–119 (2000)PubMedCrossRef E. Maiorano, A. Ciampolillo, G. Viale et al., Insulin-like growth factor 1 expression in thyroid tumors. Appl. Immunohistochem. Mol. Morphol. 8(2), 110–119 (2000)PubMedCrossRef
19.
Zurück zum Zitat S. Masood, L.J. Auguste, A. Westerband et al., Differential oncogenic expression in thyroid follicular and Hürthle cell carcinomas. Am. J. Surg. 166(4), 366–368 (1993)PubMedCrossRef S. Masood, L.J. Auguste, A. Westerband et al., Differential oncogenic expression in thyroid follicular and Hürthle cell carcinomas. Am. J. Surg. 166(4), 366–368 (1993)PubMedCrossRef
20.
Zurück zum Zitat M.H. Takahashi, G.A. Thomas, E.D. Williams, Evidence for mutual interdependence of epithelium and stromal lymphoid cells in a subset of papillary carcinomas. Br. J. Cancer 72(4), 813–817 (1995)PubMedCrossRef M.H. Takahashi, G.A. Thomas, E.D. Williams, Evidence for mutual interdependence of epithelium and stromal lymphoid cells in a subset of papillary carcinomas. Br. J. Cancer 72(4), 813–817 (1995)PubMedCrossRef
21.
Zurück zum Zitat F. Minuto, A. Barreca, P. Del Monte et al., Immunoreactive Insulin-like growth factor 1 (IGF-1) and IGF-1 binding protein content in human thyroid tissue. J. Clin. Endocrinol. Metab. 68(3), 621–626 (1989)PubMedCrossRef F. Minuto, A. Barreca, P. Del Monte et al., Immunoreactive Insulin-like growth factor 1 (IGF-1) and IGF-1 binding protein content in human thyroid tissue. J. Clin. Endocrinol. Metab. 68(3), 621–626 (1989)PubMedCrossRef
22.
Zurück zum Zitat T. Yashiro, M. Arai, K. Shizume et al., Increased activity of insulin-like growth factor-binding protein in human thyroid papillary cancer tissue. Jpn. J. Cancer Res. 85(1), 46–52 (1994)PubMedCrossRef T. Yashiro, M. Arai, K. Shizume et al., Increased activity of insulin-like growth factor-binding protein in human thyroid papillary cancer tissue. Jpn. J. Cancer Res. 85(1), 46–52 (1994)PubMedCrossRef
23.
Zurück zum Zitat E. Surmacz, M. Bartucci, Role of estrogen receptor alpha in modulating IGF-1 receptor signaling and function in breast cancer. J. Exp. Clin. Cancer Res. 23(3), 385–394 (2004)PubMed E. Surmacz, M. Bartucci, Role of estrogen receptor alpha in modulating IGF-1 receptor signaling and function in breast cancer. J. Exp. Clin. Cancer Res. 23(3), 385–394 (2004)PubMed
24.
Zurück zum Zitat M. Eszlinger, K. Krohn, J. Kratzsch et al., Growth factor expression in cold and hot thyroid nodules. Thyroid 11(2), 125–135 (2001)PubMedCrossRef M. Eszlinger, K. Krohn, J. Kratzsch et al., Growth factor expression in cold and hot thyroid nodules. Thyroid 11(2), 125–135 (2001)PubMedCrossRef
25.
Zurück zum Zitat T. O’Connell, D.R. Clemmons, IGF-1/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J. Clin. Endocrinol. Metab. 87(9), 4356–4360 (2002)PubMedCrossRef T. O’Connell, D.R. Clemmons, IGF-1/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J. Clin. Endocrinol. Metab. 87(9), 4356–4360 (2002)PubMedCrossRef
26.
Zurück zum Zitat D.D. Karp, L.G. Paz-Ares, S. Novello et al., Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol. 27(15), 2516–2522 (2009)PubMedCrossRef D.D. Karp, L.G. Paz-Ares, S. Novello et al., Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol. 27(15), 2516–2522 (2009)PubMedCrossRef
27.
Zurück zum Zitat D.R. Clemmons, Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat. Rev. Drug Discov. 6(10), 821–833 (2007)PubMedCrossRef D.R. Clemmons, Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat. Rev. Drug Discov. 6(10), 821–833 (2007)PubMedCrossRef
28.
Zurück zum Zitat P. Haluska, J.M. Carboni, C. TenEyck et al., HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 7(9), 2589–2598 (2008)PubMedCrossRef P. Haluska, J.M. Carboni, C. TenEyck et al., HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 7(9), 2589–2598 (2008)PubMedCrossRef
29.
Zurück zum Zitat Q.W. Fan, C.K. Cheng, T.P. Nicholaides et al., A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67(17), 7960–7965 (2007)PubMedCrossRef Q.W. Fan, C.K. Cheng, T.P. Nicholaides et al., A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67(17), 7960–7965 (2007)PubMedCrossRef
30.
Zurück zum Zitat Y. Wang, P. Lipari, X. Wang et al., A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol. Cancer Ther. 9(2), 410–418 (2010)PubMedCrossRef Y. Wang, P. Lipari, X. Wang et al., A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol. Cancer Ther. 9(2), 410–418 (2010)PubMedCrossRef
31.
Zurück zum Zitat E.J. Gallagher, D. LeRoith, The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol. Metab. 21(10), 610–618 (2010)PubMedCrossRef E.J. Gallagher, D. LeRoith, The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol. Metab. 21(10), 610–618 (2010)PubMedCrossRef
Metadaten
Titel
Expression and significance of IGF-1 and IGF-1R in thyroid nodules
verfasst von
Ying-Jian Liu
Wei Qiang
Jing Shi
Si-Qing Lv
Mei-Ju Ji
Bing-Yin Shi
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9864-z

Weitere Artikel der Ausgabe 1/2013

Endocrine 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.